GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (STU:24H) » Definitions » Sale Of Business

Hansa Biopharma AB (STU:24H) Sale Of Business : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hansa Biopharma AB Sale Of Business?

Hansa Biopharma AB's sale of business for the three months ended in Sep. 2024 was €0.00 Mil. It means Hansa Biopharma AB gained €0.00 Mil from selling business. Hansa Biopharma AB's sale of business for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Jun. 2024 ), Hansa Biopharma AB gained the same money from selling business in Sep. 2024 (€0.00 Mil).


Hansa Biopharma AB Sale Of Business Historical Data

The historical data trend for Hansa Biopharma AB's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Sale Of Business Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.50 - - - -

Hansa Biopharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hansa Biopharma AB Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansa Biopharma AB Sale Of Business Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines